English

Wilson Therapeutics AB (publ) Interim Report January 1 – September 30, 2016

Report this content

Clinical trial on track, final results expected before year-end.

July 1 – September 30, 2016

  • Net sales amounted to SEK 0.0 M (0.0)
  • Loss for the period was SEK 31.9 M (loss: 18.6)
  • Loss per share, before and after dilution, totaled SEK 1.24 (loss: 14.61)
  • At September 30, cash and cash equivalents amounted to SEK 415.6 M (9.9)

January 1 – September 30, 2016

  • Net sales amounted to SEK 0.0 M (0.0)
  • Loss for the period was SEK 81.1 M (loss: 49.1)
  • Loss per share, before and after dilution, totaled SEK 5.81 (loss: 38.69)

Significant events during the period January 1 – September 30, 2016

  • A new share issue raised SEK 39.9 M after issue costs
  • Resolution regarding a 1:10 share split implemented
  • Data from the ongoing Phase 2 trial of WTX101 presented at major European conferences
  • Wilson Therapeutics listed in the Mid Cap segment on Nasdaq Stockholm, raising SEK 402.7 M after issue costs
  • Ongoing phase 2 study fully enrolled
  • Management team expanded

Significant events after the end of the reporting period

  • Data from the ongoing Phase 2 trial of WTX101 presented at major US medical conference

”Preliminary data from our ongoing phase 2 trial continue to indicate that WTX101 has the potential to address the unmet medical needs in Wilson Disease, and we are set to release final topline data from the study before the end of the year.”

Jonas Hansson, CEO, Wilson Therapeutics.

   
About Wilson Therapeutics
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases. Wilson Therapeutics’ lead product, WTX101, is initially being developed as a novel treatment for Wilson Disease and is currently being evaluated in a Phase 2 clinical study. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.

More information is available at www.wilsontherapeutics.com.

 

For further information contact:
Jonas Hansson, CEO, Wilson Therapeutics AB
Telephone: +46 8 796 00 00
Email: jonas.hansson@wtx.se

Wilson Therapeutics AB (publ)
Corp. Reg. No. 556893-0357
Västra Trädgårdsgatan 15
SE-111 53 Stockholm, Sweden

   
The information in the interim report is such that Wilson Therapeutics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on November 25, 2016 at 8:00 a.m. CET.

Tags:

Wilson Therapeutics Q3 2016

Documents & Links